Aduro BioTech

Aduro BioTech is a clinical-stage biopharmaceutical company headquartered in Berkeley, California. The company employs 79 people and has reported annual revenue of $15 million. Aduro BioTech is focused on developing innovative therapies that leverage the body's natural immune system to treat various challenging diseases. Aduro BioTech specializes in developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways. Their product candidates are being investigated for potential applications in cancer, autoimmune, and inflammatory diseases. ADU-S100 (MIW815) is a promising candidate that aims to activate the intracellular STING receptor, potentially triggering a potent tumor-specific immune response in patients with certain types of metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody, is being explored as a treatment for IgA nephropathy by blocking the binding of APRIL to the BCMA and TACI receptors. Aduro BioTech actively collaborates with several leading global pharmaceutical companies to expand its product pipeline and accelerate the development of new therapies. Through these strategic partnerships, Aduro aims to bring innovative treatments to patients worldwide. For more information on Aduro BioTech and its therapeutic pipeline, please visit their website at aduro.com.